Repositioning Candidate Details
| Candidate ID: | R0953 |
| Source ID: | DB06244 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Trafermin |
| Synonyms: | Recombinant human basic fibroblast growth factor; rhbFGF; Trafermin |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | -- |
| CAS Number: | 131094-16-1 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Trafermin, or basic fibroblast growth factor 2 (bFGF) is a recombinant human growth factor used to stimulate angiogenesis and keratinization in wound healing. It stimulates migration of monocytes, neutrophils, macrophages, fibroblasts and also assists in creation of granulation tissue (the tissue that replaces fibrin clots in healing wounds). |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|